title: Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis.
abstract: Plasmin is a broad-spectrum serine proteinase, which is presumed to cleave many extracellular proteins and affect angiogenesis. In the present work, we studied the effect of two different inhibitors of plasmin (epsilon-aminocaproic and alpha(2)-antiplasmin) on angiogenesis in vivo using the chicken embryo chorioallantoic membrane assay, and in vitro using human umbilical vein endothelial cells. Epsilon-aminocaproic acid inhibited, while alpha(2)-antiplasmin induced, angiogenesis, as well as human umbilical vein endothelial cell proliferation, migration and tube formation on matrigel in a dose-dependent manner. Since plasmin has been implicated in the production of angiostatin, we studied the effect of the two plasmin inhibitors on angiostatin protein amounts in the chicken embryo chorioallantoic membrane. In this tissue, the 38- and 45-kDa isoforms of angiostatin are differentially affected by the two inhibitors: epsilon-aminocaproic acid increased, while alpha(2)-antiplasmin decreased the amounts of both isoforms. These data suggest that plasmin may have an antiangiogenic role in vivo through generation of angiostatin. Moreover, plasmin inhibitors differentially affect in vivo angiogenesis, depending on the mechanism by which they inhibit plasmin activity.
authors.affiliation: Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras GR 26504, Greece.
authors.forename: Maria
authors.initials: M
authors.lastname: Hatziapostolou
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Katsoris
authors.forename: Evangelia
authors.initials: E
authors.lastname: Papadimitriou
mesh_terms: D015119:Aminocaproic Acid / Q000494:pharmacology*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D043168:Angiostatins; D000818:Animals; D002478:Cells, Cultured; D002642:Chick Embryo; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005341:Fibrinolysin / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects* / Q000502:physiology; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D010958:Plasminogen / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D000979:alpha-2-Antiplasmin / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D010446:Peptide Fragments; D000979:alpha-2-Antiplasmin; D043168:Angiostatins; D010958:Plasminogen; D005341:Fibrinolysin; D015119:Aminocaproic Acid